New platform unites polycystic kidney disease data for near-real-time analysis
The medical sector generates vast amounts of valuable data. However, this information is often stored in different systems and is only analyzed in isolated instances for research projects. The opportunity to pool data for the purpose of improving patient care and research is often overlooked.
A groundbreaking digital platform, MEDA-PKD (MEdical DAta translation service of Polycystic Kidney Disease), has been developed by a research team led by Dr. Roman-Ulrich Müller. This platform integrates clinical, laboratory, imaging, medication, and quality of life data for near-real-time analysis of autosomal dominant polycystic kidney disease, affecting over 7 million people worldwide.
By pooling data from various sources, MEDA-PKD enables researchers to learn more quickly from patient experiences and apply this knowledge to improve personalized care. The platform has already shown that tolvaptan, the only medicine specifically authorized for polycystic kidney disease treatment, slows down kidney function decline.
User-friendly evaluations from seven experienced doctors indicate a 72% reduction in time required to compile information for consultations on tolvaptan therapy. The platform's potential extends beyond polycystic kidney disease, with plans to adapt the basic technical framework for other chronic kidney diseases, heart failure, cystic fibrosis, and cancer, ultimately contributing to a learning health care system that continuously generates new insights from healthcare provision data.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
